Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06108219 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)
A Phase 2 study of Non-alcoholic Steatohepatitis (NASH) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), sponsored by Corcept Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 175
- Enrollment target
- 20
- Study locations
NCT06108219: Active Phase 2 study of Non-alcoholic Steatohepatitis (NASH) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), sponsored by Corcept Therapeutics.
NCT06108219 is a Phase 2 study of Non-alcoholic Steatohepatitis (NASH) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) that is active but no longer recruiting, run by Corcept Therapeutics. The registered enrollment target is 175 participants, roughly in line with the 186-participant average among 16 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target. The trial reports 20 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06108219, a Phase 2 study of Non-alcoholic Steatohepatitis (NASH) and Metabolic Dysfunction-Associated Steatohepatitis (MASH), is active but no longer recruiting, sponsored by Corcept Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 175 participants
- Enrollment target
- 20
- Study locations
Study Summary
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH)
Conditions Studied
Interventions
- DRUG Miricorilant (Cohort A)
- DRUG Placebo (Cohort A)
- DRUG Miricorilant (Cohort B)
- DRUG Placebo (Cohort B)
Study Locations (20)
Florida
- Site #452 - Boca Raton
- Site # 101 - Gainesville
- Site #465 - Hallandale
- Site #430 - Hialeah Gardens
- Site #458 - Lakewood Rch
- Site #475 - Largo
- Site #438 - Miami Lakes
- Site #460 - Viera
California
- Site #378 - Huntington Park
- Site #439 - Lancaster
- Site #469 - Long Beach
- Site #373 - Los Angeles
- Site #214 - Panorama City
- Site #233 - Santa Ana
Louisiana
- Site #453 - Houma
- Site #451 - Marrero
- Site #061 - Metairie
Arizona
- Site #207 - Chandler
- Site #209 - Tucson
Maryland
- Site #440 - Rockville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 175 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2026-09 |
| Phase | Phase 2 |
What the registry record for NCT06108219 still lists
NCT06108219 is an interventional study that assigns participants to a tested intervention. The registered 175 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 186-participant average among 16 other Non-alcoholic Steatohepatitis (NASH) trials with a reported enrollment target.
The record links to 2 conditions, with Non-alcoholic Steatohepatitis (NASH) appearing as the primary indexed condition, and to 4 interventions - of which Miricorilant (Cohort A) is the first listed.
NCT06108219 names 20 study sites across 5 states, led by Florida, California, Louisiana.
Frequently Asked Questions
What is clinical trial NCT06108219 about?
NCT06108219 is a clinical study titled "A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)". A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis (MONARCH)
What is the current status of trial NCT06108219?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 175 participants. The study started on 2023-10-25. Estimated completion is 2026-09.
What conditions does trial NCT06108219 study?
This clinical trial studies the following conditions: Non-alcoholic Steatohepatitis (NASH), Metabolic Dysfunction-Associated Steatohepatitis (MASH).
What interventions are being tested in trial NCT06108219?
The interventions under investigation include: Miricorilant (Cohort A) (DRUG), Placebo (Cohort A) (DRUG), Miricorilant (Cohort B) (DRUG), Placebo (Cohort B) (DRUG).
Who is sponsoring clinical trial NCT06108219?
This trial is sponsored by Corcept Therapeutics, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06108219 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Louisiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Steatohepatitis (NASH)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06108219's enrollment target sits among peer trials
175 7th of 16 higher than 10 of 16 other Non-alcoholic Steatohepatitis (NASH) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-alcoholic Steatohepatitis (NASH) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of Rencofilstat in Subjects With NASH and Advanced Liver Fibrosis
ACTIVE NOT RECRUITING · Phase 2
-
A Phase ll Study of IMM-124E for Patients With Non-alcoholic Steatohepatitis
COMPLETED · Phase 2
-
Phase 2b Study in NASH to Assess IVA337
COMPLETED · Phase 2
-
IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
COMPLETED · Phase 2
-
Safety, Tolerability, and Efficacy of GS-4997 Alone or in Combination With Simtuzumab (SIM) in Adults With Nonalcoholic Steatohepatitis (NASH) and Fibrosis Stages F2-F3
COMPLETED · Phase 2
-
A Phase 2b Study of Icosabutate in Fatty Liver Disease
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04722341 · 175 participants · NA
Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators
- NCT05094037 · 175 participants · NA
Orthotic Treatment of Diabetic Foot Ulcers
- NCT05165745 · 175 participants · NA
Stick2PrEP Cisgender Women and Trans Individuals
- NCT05312255 · 175 participants · NA
Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI